Oncology
11 - 50 employees
Founded 2018
𧬠Biotechnology
π Pharmaceuticals
π° $10M Post-IPO Equity on 2022-03
September 27
Oncology
11 - 50 employees
Founded 2018
𧬠Biotechnology
π Pharmaceuticals
π° $10M Post-IPO Equity on 2022-03
β’ Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. β’ We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune disease. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. β’ Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. β’ We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. β’ With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. β’ The Pharmacovigilance Scientist (PVS) participates in the development and planning of safety strategies for assigned products in the clinical development and post-marketing. This will include safety data aggregation, review and analysis to support appropriate safety interpretation and benefit-risk assessment. The PVS will play essential role in developing PV/Safety documents in collaboration with other PV team members, and including cross-functional teams e.g., medical, clinical operations, regulatory affairs, Clin Pharm, and translational sciences.
β’ MS, PhD, or PharmD β’ Previous safety or relevant experience in the pharmaceutical/biotech industry or health authority required, typically with at least 5 years of experience in PV/drug safety and risk management (preferably clinical development) β’ Passion, dedication, and a can-do attitude to the career of PVS β’ Good written and verbal communication skills β’ Ability to utilize safety system database (Argus) for purposes of medical case review and simple queries β’ Knowledge of current and emerging regulatory requirements and expectations including EMA GVP Modules, FDA IND and NDA reporting requirements, global risk management requirements, ICH, CIOMS β’ Knowledge and experience in medical oncology and/or immunology is preferred β’ Ability to effectively present to cross-functional teams is required. β’ Have led the authoring/preparation of aggregate safety reports (DSURs) for products to meet regulatory requirements
Apply NowSeptember 27
Vaxcyte seeks Associate Director to lead polysaccharide commercialization for vaccines.
πΊπΈ United States β Remote
π΅ $190k - $197k / year
β° Full Time
π Senior
π Director
π¦ H1B Visa Sponsor
September 27
Senior Director for Precision Diagnostics at Telix Pharmaceuticals in the US
September 27
Oversee Data Development group at Verana Health, leveraging real-world healthcare data.
πΊπΈ United States β Remote
π΅ $245k - $275k / year
π° $150M Series E on 2022-01
β° Full Time
π Senior
π Director
π¦ H1B Visa Sponsor
September 27
Senior Director managing Product Safety at Torc, a leader in autonomous driving.
πΊπΈ United States β Remote
π΅ $262.1k - $314.5k / year
β° Full Time
π Senior
π Director
π¦ H1B Visa Sponsor
September 27
Serve as a trusted partner delivering tailored solutions in Private Equity.
πΊπΈ United States β Remote
π° $1.5M Venture Round on 2021-02
β° Full Time
π Senior
π Director
π¦ H1B Visa Sponsor